Short Interest in Cel-Sci Corporation (NYSEAMERICAN:CVM) Declines By 64.0%

Cel-Sci Corporation (NYSEAMERICAN:CVM) was the recipient of a large drop in short interest in the month of May. As of May 15th, there was short interest totaling 255,031 shares, a drop of 64.0% from the April 30th total of 708,414 shares. Based on an average trading volume of 1,289,720 shares, the days-to-cover ratio is presently 0.2 days. Currently, 3.3% of the shares of the company are sold short.

Hedge Funds Weigh In On Cel-Sci

Hedge funds have recently modified their holdings of the company. MAI Capital Management increased its position in shares of Cel-Sci by 18.4% during the 3rd quarter. MAI Capital Management now owns 76,861 shares of the company’s stock valued at $707,000 after purchasing an additional 11,928 shares during the period. HRT Financial LP acquired a new position in shares of Cel-Sci during the 4th quarter valued at $60,000. US Bancorp DE acquired a new position in shares of Cel-Sci during the 3rd quarter valued at $80,000. Bank of America Corp DE increased its position in shares of Cel-Sci by 2,188.2% during the 2nd quarter. Bank of America Corp DE now owns 40,981 shares of the company’s stock valued at $94,000 after purchasing an additional 39,190 shares during the period. Finally, State Street Corp increased its position in shares of Cel-Sci by 9.9% during the 4th quarter. State Street Corp now owns 25,570 shares of the company’s stock valued at $134,000 after purchasing an additional 2,300 shares during the period. 12.08% of the stock is currently owned by institutional investors and hedge funds.

Cel-Sci Stock Performance

CVM traded up $0.06 during trading hours on Friday, hitting $1.54. The company’s stock had a trading volume of 188,823 shares, compared to its average volume of 885,790. Cel-Sci has a fifty-two week low of $0.89 and a fifty-two week high of $13.48. The company has a current ratio of 0.60, a quick ratio of 0.54 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $13.07 million, a PE ratio of -0.16 and a beta of 0.54. The company has a 50-day simple moving average of $2.85 and a 200 day simple moving average of $4.49.

Cel-Sci (NYSEAMERICAN:CVM) last posted its earnings results on Friday, May 15th. The company reported ($0.67) EPS for the quarter.

Cel-Sci Company Profile

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.